NCT00516919

Brief Summary

This is a research study designed to examine the effectiveness of an obesity medication (orlistat) given in addition to behavioral weight loss therapy. Participants will be obese monolingual (Spanish-speaking only) men and women.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
79

participants targeted

Target at P50-P75 for phase_4 obesity

Timeline
Completed

Started Aug 2007

Typical duration for phase_4 obesity

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2007

Completed
14 days until next milestone

First Submitted

Initial submission to the registry

August 15, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

August 16, 2007

Completed
3.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2010

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2010

Completed
2.2 years until next milestone

Results Posted

Study results publicly available

February 7, 2013

Completed
Last Updated

April 2, 2020

Status Verified

March 1, 2020

Enrollment Period

3.3 years

First QC Date

August 15, 2007

Results QC Date

July 31, 2012

Last Update Submit

March 31, 2020

Conditions

Keywords

ObesityBinge EatingMonolingual Hispanic PersonsOrlistatBehavioral Weight Loss Treatment

Outcome Measures

Primary Outcomes (1)

  • Participant BMI

    Body Mass Index (BMI)

    4 months and 6 month follow-up

Study Arms (2)

1

EXPERIMENTAL

Xenical + behavioral intervention

Drug: Xenical + behavioral intervention

2

ACTIVE COMPARATOR

Placebo + behavioral intervention

Behavioral: Behavioral intervention + placebo

Interventions

120 mg TID; Behavioral weight loss in Spanish

Also known as: Xenical
1

Behavioral weight loss treatment in Spanish Placebo TID

2

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Monolingual Spanish Speaking
  • Obese (BMI \>= 30)

You may not qualify if:

  • Pregnancy
  • Current cardiac disease
  • Serious neurologic illnesses

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Hispanic Clinic of the Connecticut Mental Health Center

New Haven, Connecticut, 06511, United States

Location

Yale Department of Psychiatry

New Haven, Connecticut, 06519, United States

Location

Related Publications (2)

  • Grilo CM, Kerrigan SG, Lydecker JA, White MA. Physical activity changes during behavioral weight loss treatment by Latinx patients with obesity with and without binge eating disorder. Obesity (Silver Spring). 2021 Dec;29(12):2026-2034. doi: 10.1002/oby.23278. Epub 2021 Sep 28.

  • Grilo CM, White MA. Orlistat with behavioral weight loss for obesity with versus without binge eating disorder: randomized placebo-controlled trial at a community mental health center serving educationally and economically disadvantaged Latino/as. Behav Res Ther. 2013 Mar;51(3):167-75. doi: 10.1016/j.brat.2013.01.002. Epub 2013 Jan 18.

MeSH Terms

Conditions

ObesityBulimia

Interventions

OrlistatBehavior Therapy

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsHyperphagiaSigns and Symptoms, Digestive

Intervention Hierarchy (Ancestors)

LactonesOrganic ChemicalsPsychotherapyBehavioral Disciplines and Activities

Results Point of Contact

Title
Dr. Carlos Grilo
Organization
Yale University School of Medicine

Study Officials

  • Carlos M Grilo, PhD

    Yale University

    PRINCIPAL INVESTIGATOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 4
Allocation
RANDOMIZED
Masking
QUADRUPLE
Who Masked
PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

August 15, 2007

First Posted

August 16, 2007

Study Start

August 1, 2007

Primary Completion

December 1, 2010

Study Completion

December 1, 2010

Last Updated

April 2, 2020

Results First Posted

February 7, 2013

Record last verified: 2020-03

Locations